PTU - Polskie Towarzystwo Urologiczne
home page
current numbers
archival numbers
list of articles:
list przewodni/covering letter
editor
Scientific Committee
publisher
subscription
advertising
important links

Prostate cancer bone metastases � signs, diagnosis and pathogenesis
Article published in Urologia Polska 2006/59/1.

authors

Andrzej Borówka, Jakub Dobruch, Artur A. Antoniewicz
Klinika Urologii Centrum Medycznego Kształcenia Podyplomowego, I Zespół Dydaktyki Urologicznej - Oddział Urologii Międzyleskiego Szpitala Specjalistycznego w Warszawie

keywords

prostate, prostate cancer, bone metastases, pathogenesis, diagnosis

summary

Prostate cancer (PCa, prostate adenocarcinoma) is one of the most prevalent cancers in men. It is found to form metastasis usually within the bones. Bone mets appear in 80-85% patients who die of prostate cancer. The risk of their presence increases with stage, Gleason score and PSA. Skeletal related events resulting from bone metastasis are the cause of poor quality of life and poor prognosis. Initially bone metastasis does not produce symptoms or signs before more advanced stages, when severe pain occurs. Scintigraphy remains the most sensitive tool for diagnosing prostate cancer bone metastasis.
Present knowledge regarding pathogenesis of prostate cancer bone metastasis has been improved recently. It was shown that normal bone cells were involved in growth of prostate cancer cells. In this paper diagnosis and pathogenesis of bone mets of prostate cancer are presented.

references

  1. 1. Parkin DM, Bray FI, Devesa SS: Cancer burden in the year 2000: the global picture. Eur J Cancer 2001, 37 (Suppl 8), 4-66.
  2. 2. Didkowska J, Wojciechowska U, Tarkowski W, Zatoński W: Nowotwory złośliwe w Polsce w 2002 roku. Centrum Onkologii ? Instytut im. M. Skłodowskiej-Curie, Krajowy Rejestr Nowotworów, Warszawa 2005, 72-76.
  3. 3. Stamey TA: Cancer of the prostate: an analysis of some important contributions and dilemmas. Monographs in Urology 1982, 3, 67-74.
  4. 4. Stamey TA, Donaldson AN, Yemoto CE et al: Histological and clinical findings in 896 consecutive prostates treated only with radical retropubic prostatectomy: epidemiologic significance of annual changes. J Urol 1998, 160, 2412-2417.
  5. 5. Perrotti M, Rabbani F, Farkas A et al: Trends in poorly differentiated prostate cancer 1973-1994, observations from the Surveillance, Epidemiology and End Results Database. J Urol 1998, 160, 811-815.
  6. 6. Paquette EL, Sun L, Paquette LR et al: Improved prostate cancer-specific survival and other disease parameters: impact of prostate-specific antigen testing. Urology 2002, 60, 756-759.
  7. 7. Lee N, Fawaaz R, Olsson CA et al: Which patients with newly diagnosed prostate cancer need a radionuclide bone scan? An analysis based on 631 patients. Int J Oncology Biol Phys 2000, 48, 1443-1446.
  8. 8. Akimoto S, Furuya Y, Akakura K et al: Relationship between prostate-specific antigen, clinical stage, and degree of bone metastasis in patients with prostate cancer: comparison with prostatic acid phosphatase and alkaline phosphatase. Int J Urol 1997, 4, 572-575.
  9. 9. Bubendorf L, Schopfer A, Wagner U et al: Metastatic patterns of prostate cancer: an autopsy study of 1589 patients. Hum Patrol 2000, 31, 578-583.
  10. 10. Poor G, Atkinson EJ, Lewallen DG et al: Age-related hip fractures in men: clinical spectrum and short-term outcomes. Osteoporiosis Int 1995, 5, 419-426.
  11. 11. Coleman RE: Skeletal complications of malignancy. Cancer 1997, 80 (Suppl) 1588-1594.
  12. 12. Oefelein MG, Ricchuti V, Conrad W, Resnick MI: Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 2002, 16, 1005-1007.
  13. 13. Berruti A, Dogliotti L, Bitossi R et al: Incidence of skeletal complicastions in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline. J Urol 2000, 164, 1248-1253.
  14. 14. Jakobs S-C: Spread of prostatic cancer to bone. Urology 1983, 21, 337-344.
  15. 15. Karlin BI, Andriole GL: The natural history, skeletal complications and management of bone metastases in patients with prostate carcinoma. Cancer 2000, 88 (Supl), 2989-2994.
  16. 16. Isaacs JT: The biology of hormone refractory prostate cancer. Why does it develop? Urol Clin North Am 1999, 26, 263-273.
  17. 17. Carlin BI, Andriole GL: The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer 2000, 88 (suppl), 2989-2994.
  18. 18. Lepor H, Ross A, Walsh PC: The influence of hormonal therapy on survival of men with advanced prostatic cancer. J Urol 1982, 128: 335-340.
  19. 19. Eisenberger MA, Crawford ED, Wolf M et al: Prognostic factors in stage D2 prostate cancer: important implications for future trials: results of a Co-operative Intergroup Study (INT 0036). Hemin Oncol 1004, 21, 613-619.
  20. 20. Oefelein MG, Ricchiuti V, Konrad W, Resnick MI: Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 2002, 168, 1005-1007.
  21. 21. Rolski J: Anemia u chorych z rozsiewem procesu nowotworowego do kości, w: Przerzuty nowotworowe do kości ? nowe kierunki leczenia, red. Pawlicki M, á-Medica Press, Bielsko-Biała 2004, rozdz. 13, str. 172-178.
  22. 22. Wolff JM, Ittel TH, Borchers H et al: Metastatic workup of patients with prostate cancer emploing alkaline phosphatase and skeletal alkaline phosphatase. Anticancer Res 1999, 19, 2653-2655.
  23. 23. Gerber G, Chodak GW: Assessment of value of routine bone scans in patients with newly diagnosed prostate cancer. Urology 1991, 37, 418-422.
  24. 24. Buell U, Kleinhans E, Zorn-Bopp E et al: A comparison of bone imaging with Tc-99m DPD and Tc-99m MDP: concise communication. J Nucl Med 1982, 23, 214-217.
  25. 25. Paulson DF: The impact of current staging procedures in assessing disease extent of prostatic adenocarcinoma. J Urol 1979, 121, 300-302.
  26. 26. Soloway MS, Hardiman SW, Hickey D: Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 1988, 61, 195-202.
  27. 27. Ball JD, Maynard CD: Nuclear imaging in urology. Urol Clin North Am 1979, 6, 321-342.
  28. 28. Lentle BC, McGowan DG, Dierich H: Technetium-99m polyphosphate bone scanning in carcinoma of the prostate. Br J Urol 1974, 46, 543-548.
  29. 29. Buck AC, Chisholm GD, Merrick MV, Lavender JP: Serial Fluorine-18 bone scans in the follow-up of carcinoma of the prostate. Br J Urol 1975, 47, 287-294.
  30. 30. Fochem K, Ogris E: Early recognition of bone metastases (comparative study between bone scintigraphy and x-ray examination). Acta Medica Austriaca 1976, 3, 170-176.
  31. 31. Hain SF, Maisey MN: Positron emission tomography for urological tumours. BJU International 2003, 92 (2), EBU Eur Urol Update Series 2003 (4), 159-164.
  32. 32. Israeli RS, Powell CT, Corr JG: Expression of the prostate-specific membrane antigen. Cancer Res 1994, 54, 1807-1811.
  33. 33. Chang SS, Gaudin PB, Reuter VE: Prostate-specific membrane antigen: present and future applications. Urol 2000, 55, 622-629.
  34. 34. Bermejo CE, Coursey J, Basler J: Histologic confirmation of lesions identified by Prostascint scan following definitive treatment. Urol Oncol 2003, 21, 349-352.
  35. 35. Rana A, Karamanis K, Lucas MG, Chisholm GD: Identification of metastatic disease by T category, Gleason score and serum PSA level in patients with carcinoma of the prostate. Br J Urol 1992, 69, 277-281.
  36. 36. Wolff JM, Bares R, Jung PK et al: Prostate-specific antigen as a marker of bone metastasis in patients with prostate cancer. Urol Int 1996, 56, 169-173.
  37. 37. Oesterling JE, Martin SK, Bergstralh EJ, Lowe FC: The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. JAMA 1993, 269, 57-60.
  38. 38. Miller PD, Eardley I, Kirby RS: Prostate specific antigen and bone scan correlation in the staging and monitoring of patients with prostatic cancer. Br J Urol 1992, 70, 295-298.
  39. 39. Frost HM: The origin and nature of transients in human bone remodelling dynamics. W: Clinical aspect of metabolic bone disease. (red: Frame B, Parfitt AM, Duncan H) Excerpta Medica, Amsterdam, 1973, str. 124.
  40. 40. Parfitt AM: The physiology and clinical significance of bone histomorphometric data. W: Bone histomorphometry techniques and interpretations. (red: Recker R). Boca Raton CRC Press, 1983, str. 143.
  41. 41. Berruti A, Dogliotti L, Tucci M et al: Metabolic bone disease. (red: Frame B, Parfitt AM, Duncan H) Excerpta Medica, Amsterdam, 1973, str. 124.
  42. 40. Parfitt AM: The physiology and clinical significance of bone histomorphometric data. W: Bone histomorphometry techniques and interpretations. (red: Recker R). Boca Raton CRC Press, 1983, str. 143.
  43. 41. Berruti A, Dogliotti L, Tucci M et al: Metabolic bone disease induced by prostate cancer: rationale for the use of bisphophonates. J Urol 2001, 166, 2023-2031.
  44. 42. Manolagas SC: Role of cytokines in bone resorption. Bone 1995, 17 (suppl), 63-67.
  45. 43. Teitelbaum SL: Bone resorption by osteoclasts. Science 2000, 289, 1504-1508.
  46. 44. Hofbauer LC, Khosla S, Dunstan CR et: al: The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 2000, 15, 2-12.
  47. 45. Mundy GR, Boyce B, Hughes D et al: The effects of cytokines and growth factors on osteoblastic cells. Bone (suppl) 1995, 17, 71S-75S.
  48. 46. Guise TA, Mundy GR: Cancer and bone. Endocrin Rev 1998, 19, 18-54.
  49. 47. Berruti A, Dogliotti L, Gorzegno G et al: Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases. Clin Chem 1999, 45, 1240-1247.
  50. 48. McGrath SA, Diamond T: Osteoporosis as a complication of orchiectomy in 2 elderly men with prostate cancer. J Urol 1995, 154, 535-536.
  51. 49. Berruti A, Dogliotti L, Terrone C et al: Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol 2002, 167, 2361-2367.
  52. 50. Higano CS, Stephens C, Nelson P et al: Prospective serial measurements of bone mineral density (BMD) in prostate cancer patients without bone metastases treated with intermittent androgen suppression (IAS). Proceedings ASCO 1999, 1207, 314a.

correspondence

Jakub Dobruch
Międzyleski Szpital Specjalistyczny
ul. Bursztynowa 2
04-749 Warszawa
tel. 0 503072230
kubadobr@wp.pl